Symbiotec Pharmalab IPO Details
| IPO Date | 24 to 27 Aug 2026 |
|---|---|
| Listing Date | Tuesday, Sep 1, 2026 |
| Face Value | ₹2 per share |
| Price Band | ₹938 to ₹988 per share |
| Lot Size | 15 Shares |
| Issue Type | Book Building Issue |
| Sale Type | Fresh Issue cum Offer for Sale |
| Listing At | BSE, NSE |
| Total Issue Size | ₹1,757 Cr |
| Fresh Issue | ₹150 Cr |
| Offer for Sale | 1,62,65,181 Equity Shares |
| Employee Discount | ₹90 per share |
| Market Cap at Upper Band | ₹6,244.43 Cr |
| Pre-Issue Shares | 6,16,81,496 Shares |
| Post-Issue Shares | 6,32,02,757 Shares |
Symbiotec Pharmalab IPO Timeline
| IPO Event | Date |
|---|---|
| IPO Open | Monday, Aug 24, 2026 |
| IPO Close | Thursday, Aug 27, 2026 |
| Basis of Allotment | Friday, Aug 28, 2026 |
| Refunds Initiated | Monday, Aug 31, 2026 |
| Credit to Demat Account | Monday, Aug 31, 2026 |
| Listing | Tuesday, Sep 1, 2026 |
Symbiotec Pharmalab IPO Lot Size
Investors can apply for a minimum of 15 shares, with additional bids placed in multiples of 15 shares. At the upper end of the price band, one retail lot requires ₹14,820.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 15 | ₹14,820 |
| Retail Maximum | 13 | 195 | ₹1,92,660 |
| S-HNI Minimum | 14 | 210 | ₹2,07,480 |
| S-HNI Maximum | 67 | 1,005 | ₹9,92,940 |
| B-HNI Minimum | 68 | 1,020 | ₹10,07,760 |
Symbiotec Pharmalab IPO Reservation
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers (QIB) | Not more than 50% of the Net Offer |
| Retail Individual Investors | Not less than 35% of the Net Offer |
| Non-Institutional Investors (NII) | Not less than 15% of the Net Offer |
Symbiotec Pharmalab IPO Investor Categories
| Category | Application Limit | Cut-Off |
|---|---|---|
| RII | Up to ₹2 Lakhs | Yes |
| sNII | ₹2 Lakhs – ₹10 Lakhs | No |
| bNII | Above ₹10 Lakhs | No |
| Employee | Up to ₹5 Lakhs | Yes |
| Employee + RII/NII | Employee + applicable RII/NII limits | Yes for eligible employee/RII category |
About Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited is a pharmaceutical and biotechnology company involved in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products.
The company has built its business around steroidal and corticosteroid-related APIs and has expanded its manufacturing capabilities over several decades. Its products are supplied to customers in India as well as international markets.
Symbiotec began its journey in the steroidal hormone API segment and has subsequently developed an integrated manufacturing platform covering multiple stages of production. The company operates manufacturing facilities designed to support chemical synthesis and fermentation activities.
Its regulatory credentials include approvals and certifications associated with major international pharmaceutical markets, including US FDA and EU-GMP standards.
As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with chemical synthesis capacity of up to 584.67 metric tonnes and fermentation capacity of approximately 300 kilolitres.
Symbiotec Pharmalab IPO Key Strengths
Symbiotec Pharmalab IPO Financial Performance
The company’s financial performance shows growth in total income and profit during FY2026 compared with FY2025. Total income rose from ₹755.98 crore to ₹872.26 crore, while profit after tax increased from ₹96.79 crore to ₹109.90 crore.
The company also reported an increase in net worth, while total borrowings declined compared with the previous financial year.
| Particulars | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Total Assets | ₹1,780.79 Cr | ₹1,579.65 Cr | ₹1,294.79 Cr |
| Total Income | ₹872.26 Cr | ₹755.98 Cr | ₹723.33 Cr |
| Profit After Tax | ₹109.90 Cr | ₹96.79 Cr | ₹100.06 Cr |
| EBITDA | ₹231.97 Cr | ₹206.11 Cr | ₹177.04 Cr |
| Net Worth | ₹1,158.64 Cr | ₹821.15 Cr | ₹720.68 Cr |
| Reserves & Surplus | ₹1,145.95 Cr | ₹810.03 Cr | ₹709.54 Cr |
| Total Borrowings | ₹387.91 Cr | ₹540.92 Cr | ₹247.21 Cr |
Figures are in ₹ crore unless otherwise stated.
Symbiotec Pharmalab IPO Key Performance Indicators
| KPI | FY2026 | FY2025 |
|---|---|---|
| ROE | 11.19% | 12.66% |
| ROCE | 11.56% | 11.80% |
| RoNW | 9.48% | 11.79% |
| PAT Margin | 12.60% | 12.80% |
| EBITDA Margin | 26.59% | 27.26% |
| NAV | ₹184.69 | ₹150.17 |
| Price to Book Value | 5.35 | 6.58 |
Symbiotec Pharmalab IPO Valuation
Based on the supplied IPO valuation figures, Symbiotec Pharmalab has an estimated post-issue market capitalisation of approximately ₹6,244.43 crore at the upper end of the price band.
| Valuation Metric | Pre-IPO | Post-IPO |
|---|---|---|
| EPS | ₹17.82 | ₹17.39 |
| P/E | 55.44x | 56.81x |
| Market Capitalisation | ₹6,094 Cr | ₹6,244.43 Cr |
Symbiotec Pharmalab IPO Objectives
The fresh issue component is intended to provide funds for corporate requirements, with a significant portion proposed for reducing the company’s outstanding debt.
| Purpose | Amount |
|---|---|
| Prepayment and/or repayment of certain outstanding borrowings | ₹112.50 Cr |
| General Corporate Purposes | Balance Amount |
Symbiotec Pharmalab Shareholding Pattern
| Category | Pre-IPO Holding |
|---|---|
| Promoter & Promoter Group | 34.47% |
| Public | 65.53% |
| Total | 100% |
The company promoters are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.
Symbiotec Pharmalab IPO Offer for Sale
A substantial portion of the IPO is an offer for sale, through which existing shareholders will sell their equity holdings. The OFS component is valued at up to ₹1,607 crore at the issue price.
| Selling Shareholder | Category | Estimated Value |
|---|---|---|
| Satwani Holdings LLP | Promoter | ₹144 Cr |
| Rosewood Investments | Other | ₹988 Cr |
| India Business Excellence Fund III | Corporate | ₹475 Cr |
| Total | ₹1,607 Cr |
Symbiotec Pharmalab IPO Review
What Is Symbiotec Pharmalab IPO GMP?
GMP, or Grey Market Premium, is an unofficial indicator that reflects the premium or discount at which an IPO may be traded in the grey market before its stock-market listing.
Grey-market transactions are outside the official stock exchange mechanism. GMP can therefore change rapidly with investor demand, market conditions and expectations surrounding the IPO.
Investors should not treat GMP as a guaranteed listing price or as an official indication from the company or stock exchanges.
Symbiotec Pharmalab IPO Registrar
The IPO registrar is responsible for processing applications, maintaining application records and handling the allotment and refund process.
Phone: 022-49186000
Email: symbiotecpharmalab.ipo@in.mpms.mufg.com
Symbiotec Pharmalab IPO Lead Managers
| No. | Book Running Lead Manager |
|---|---|
| 1 | JM Financial Ltd. |
| 2 | Avendus Capital Pvt. Ltd. |
| 3 | Motilal Oswal Investment Advisors Ltd. |
| 4 | Nomura Financial Advisory & Securities (India) Pvt. Ltd. |
Symbiotec Pharmalab Contact Details
385/2, Pigdamber, Rau,
Mhow, Indore,
Madhya Pradesh – 453331
Phone: +91 731 667 6405
Email: secretarial@symbiotec.com
Symbiotec Pharmalab IPO FAQs
When will Symbiotec Pharmalab IPO open?
The IPO is scheduled to open for subscription on August 24, 2026.
When will Symbiotec Pharmalab IPO close?
The subscription window is scheduled to close on August 27, 2026.
What is the Symbiotec Pharmalab IPO price band?
The IPO price band has been fixed at ₹938 to ₹988 per equity share.
What is Symbiotec Pharmalab IPO lot size?
The minimum application size is 15 shares.
What is the minimum investment for Symbiotec Pharmalab IPO?
At the upper price of ₹988 per share, one lot of 15 shares requires an investment of ₹14,820.
What is the total size of Symbiotec Pharmalab IPO?
The issue size is approximately ₹1,757 crore, consisting of a fresh issue of up to ₹150 crore and an offer for sale of up to ₹1,607 crore.
When will Symbiotec Pharmalab IPO allotment be finalized?
The basis of allotment is expected to be finalized on August 28, 2026.
When will Symbiotec Pharmalab shares be listed?
The tentative listing date is September 1, 2026 on both BSE and NSE.
Who is the registrar of Symbiotec Pharmalab IPO?
MUFG Intime India Pvt. Ltd. is the registrar for the Symbiotec Pharmalab IPO.
Where can I check Symbiotec Pharmalab IPO GMP?
You can view the latest GMP information on the Symbiotec Pharmalab IPO GMP page on TradingMinds.
Disclaimer: This IPO article is provided for informational and educational purposes only and should not be considered investment advice. IPO dates, price bands, allotment schedules, financial information and other issue-related details can change following official announcements. Grey market premium figures are unofficial and may fluctuate significantly. Investors should read the official IPO documents, including the relevant offer documents, carefully and evaluate the risks before making any investment decision.
